BioInvent International Full Year 2024 Earnings: kr6.53 loss per share (vs kr5.02 loss in FY 2023)
BioInvent International (STO:BINV) Full Year 2024 Results
Key Financial Results
- Net loss: kr429.4m (loss widened by 30% from FY 2023).
- kr6.53 loss per share (further deteriorated from kr5.02 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BioInvent International Earnings Insights
Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Sweden.
Performance of the Swedish Biotechs industry.
The company's shares are up 15% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for BioInvent International that you should be aware of.
If you're looking to trade BioInvent International, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if BioInvent International might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:BINV
BioInvent International
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally.
Flawless balance sheet with high growth potential.
